PMID- 27858230
OWN - NLM
STAT- MEDLINE
DCOM- 20170523
LR  - 20211204
IS  - 2095-0225 (Electronic)
IS  - 2095-0217 (Linking)
VI  - 10
IP  - 4
DP  - 2016 Dec
TI  - Efficacy and safety of JAK inhibitor INC424 in patients with primary and 
      post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the 
      Chinese population.
PG  - 437-443
LID - 10.1007/s11684-016-0472-9 [doi]
AB  - A phase II study (A2202) was performed to evaluate the efficacy and safety of JAK 
      inhibitor ruxolitinib in 63 Chinese MF patients. Ruxolitinib was given twice a 
      day (bid) at a starting dose of 15 mg (n = 25) or 20 mg (n = 38) based on a 
      baseline platelet count. About 94.7% of the patients achieved a reduction in 
      spleen size, 27.0% of which exhibited significant reduction (>/= 35%) at week 24. 
      Significant improvement in debilitating constitutional symptoms, as assessed by 
      MFSAF v2.0, was observed in patients treated with ruxolitinib. Ruxolitinib 
      treatment was generally well tolerated by Chinese patients. Although the 
      treatment was associated with an increase in certain adverse events (AEs) that 
      were established as identified risks (anemia and thrombocytopenia), these AEs 
      were considered manageable in this clinical setting. Ruxolitinib provided 
      substantial reductions in splenomegaly and improvements in symptoms, and was 
      well-tolerated by Chinese patients with MF.
FAU - Du, Xin
AU  - Du X
AD  - Department of Hematology, Guangdong General Hospital, Guangdong Academy of 
      Medical Sciences, Guangzhou, 510080, China.
FAU - Zhou, Daobin
AU  - Zhou D
AD  - Department of Hematology, Peking Union Medical College Hospital, Beijing, 100730, 
      China. zhoudb@pumch.cn.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
DEP - 20161223
PL  - China
TA  - Front Med
JT  - Frontiers of medicine
JID - 101549428
RN  - 0 (Nitriles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 82S8X8XX8H (ruxolitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - China
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Nitriles
MH  - Organ Size
MH  - Polycythemia Vera/*complications
MH  - Primary Myelofibrosis/complications/*drug therapy
MH  - Protein Kinase Inhibitors/*administration & dosage/adverse effects
MH  - Pyrazoles/*administration & dosage/adverse effects
MH  - Pyrimidines
MH  - Spleen/drug effects/pathology
MH  - Thrombocythemia, Essential/*complications
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Chinese patients
OT  - JAK
OT  - myelofibrosis
OT  - ruxolitinib
EDAT- 2016/11/20 06:00
MHDA- 2017/05/24 06:00
CRDT- 2016/11/19 06:00
PHST- 2016/02/29 00:00 [received]
PHST- 2016/07/05 00:00 [accepted]
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2017/05/24 06:00 [medline]
PHST- 2016/11/19 06:00 [entrez]
AID - 10.1007/s11684-016-0472-9 [pii]
AID - 10.1007/s11684-016-0472-9 [doi]
PST - ppublish
SO  - Front Med. 2016 Dec;10(4):437-443. doi: 10.1007/s11684-016-0472-9. Epub 2016 Dec 
      23.